Citi cuts Ypsomed to 'neutral' after strong share-price run

By Reuters News

** Citi cuts Swiss drug-delivery device maker Ypsomed YPSN.S to "neutral" from "buy" after the stock's recent re-rating

** Shares are up 21% over the last month and 34% year-to-date

** Citi remains positive on Ypsomed's medium-term growth prospects, but sees a more balanced risk-reward profile at the current valuation, with few near-term catalysts before FY 2026/27 results next May

** It continues to view Ypsomed as a "high-quality asset" thanks to its attractive exposure to biologics, biosimilars and incretin therapies

** Following the company's H1 results and guidance hike, Citi increases its EPS estimates by 3-5% for fiscal years 2026/27-2030/31

** It also raises its PT to CHF 450 ($537) from CHF 425

($1 = 0.8384 Swiss francs)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.